Artivion (NYSE:AORT) Posts Earnings Results, Misses Expectations By $0.51 EPS

Artivion (NYSE:AORT) announced its quarterly earnings data on Monday. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.51), reports. Artivion had a positive return on equity of 5.15% and a negative net margin of 0.22%. The business had revenue of $97.31 million during the quarter, compared to the consensus estimate of $100.82 million. Artivion updated its FY 2025 guidance to EPS.

Artivion Stock Performance

AORT traded down $2.85 during trading on Tuesday, hitting $25.00. The stock had a trading volume of 375,415 shares, compared to its average volume of 351,872. Artivion has a one year low of $18.38 and a one year high of $32.33. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.88 and a quick ratio of 1.33. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -1,248.00 and a beta of 1.75. The company has a 50 day moving average price of $29.75 and a 200-day moving average price of $27.83.

Insider Activity

In related news, VP Andrew M. Green sold 7,618 shares of the company’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $30.00, for a total transaction of $228,540.00. Following the completion of the sale, the vice president now owns 33,503 shares of the company’s stock, valued at $1,005,090. This represents a 18.53 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Jean F. Holloway sold 8,070 shares of the company’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $30.12, for a total transaction of $243,068.40. Following the sale, the senior vice president now directly owns 153,862 shares of the company’s stock, valued at approximately $4,634,323.44. This trade represents a 4.98 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 20,017 shares of company stock valued at $600,007. 8.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several equities research analysts have issued reports on the stock. Oppenheimer lifted their price target on shares of Artivion from $30.00 to $32.00 and gave the company an “outperform” rating in a research note on Friday, November 8th. JMP Securities reaffirmed a “market outperform” rating and issued a $33.00 target price on shares of Artivion in a research report on Tuesday, December 10th. Stifel Nicolaus reduced their price target on Artivion from $33.00 to $30.00 and set a “buy” rating for the company in a research report on Tuesday. Finally, Needham & Company LLC lowered their price target on Artivion from $34.00 to $32.00 and set a “buy” rating on the stock in a research report on Tuesday. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $31.40.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.